

Intitulé du cours

Course title – Intitulé du cours	Health Econometrics
Level / Semester – Niveau /semestre	M2
School – Composante	Ecole d'Economie de Toulouse
Teacher – Enseignant responsable	Catarina Goulão
Other teacher(s) – Autre(s) enseignant(s)	
Other teacher(s) – Autre(s) enseignant(s)	
Other teacher(s) – Autre(s) enseignant(s)	
Other teacher(s) – Autre(s) enseignant(s)	
Other teacher(s) – Autre(s) enseignant(s)	
Lecture Hours – Volume Horaire CM	15h
TA Hours – Volume horaire TD	
TP Hours – Volume horaire TP	
Course Language – Langue du cours	English
TA and/or TP Language – Langue des TD et/ou TP	

Teaching staff contacts – Coordonnées de l'équipe pédagogique :

Catarina Goulão [CG]: Office T.378. email : catarina.goulao@tse-fr.eu

Course Objectives – Objectifs du cours :

The main objective is to introduce students to some of the main policy challenges and economic problems of the health care sector. For each of them I will start by exposing the economic tools and frameworks of analysis that highlight the economic mechanisms. These will then be illustrated using the most leading research applications to health care, mainly in the context of developed countries.

Prerequisites – Pré requis :

Practical information about the sessions – Modalités pratiques de gestion du cours :

Grading system – Modalités d'évaluation :

Students will be evaluated on the basis of a written paper. Work in pairs.

You will use the dataset Open Damir : base complète sur les dépenses d'assurance maladie en 2020". You can find it here:

<https://assurance-maladie.ameli.fr/etudes-et-donnees/open-damir-depenses-sante-interregimes-2020>

There is not a specific content of the paper but you should get my former approval.

Bibliography/references – Bibliographie/références :

Miscellany :

How to write nicely papers:

Alley, Michael. "The craft of Scientific writing", Springer; 4th edition (Mars 21, 2018).

Session planning – Planification des séances

A couple of papers per topic will be discussed in detail.

1. Introduction [S1].

2. Health and health behaviours [S2, S3].

Currie, J., Schwandtand, H., Thuilliez, J. (2020) “Pauvreté, Egalité, Mortalité: Mortality (In)Equality in France and the U.S.,” *Journal of Population Economics* 33, 197-231.

Almond, D., Currie, J., Duque, V. “Childhood Circumstances and Adult Outcomes: Act II,” *the Journal of Economic Literature*, Dec. 2018, 56 4, Dec. 2018, 1360–1446.

Van den Berg, GC. Pinger, PR. Schoch J. (2016) “Instrumental variable estimation of the causal effect of hunger early in life on health later in life”. *The Economic Journal* 126 (591), 465–506.

van den Berg, G., Lindeboom, M. and Portrait, F. (2006). “Economic Conditions Early in Life and Individual Mortality.” *American Economic Review*, 96 (1): 290-302.

3. Demand for health care [S4, S5].

Finkelstein, A., Einav, L., Oostrom, T., Ostriker, A., Williams, H. (2020) “Screening and Selection: The Case of Mammograms” *American Economic Review*, 110 (12) 3836–3870.

Ginsberg, J., Mohebbi, MH, Patel, RS, Brammer, L, Smolinski, MS, Brilliant, L. (2009) “Detecting influenza epidemics using search engine query data”. *Nature* 457 (7232), 1012–1014.

Theresa Kuchler, Dominic Russel, Johannes Stroebel (2021) JUE Insight: The geographic spread of COVID-19 correlates with the structure of social networks as measured by Facebook. *Journal of Urban Economics* , 103314

Jayson S. Jia , Xin Lu , Yun Yuan , Ge Xu , Jianmin Jia and Nicholas A. Christakis (2020). Population flow drives spatio-temporal distribution of COVID-19 in China. *Nature* vol 582.

4. Health Insurance [S6, S7].

Newhouse JP. “Free for all? Lessons from the RAND Health Insurance Experiment”. Cambridge, MA: Harvard University Press, 1993. ISBN 0-674-31846-3. [Paperback edition, 1996: ISBN 0-674-31914- 1.

Taubman, S., Wright, B., Bernstein, M., Gruber, J., Newhouse, JP., Allen, H., Baicker, K. and Finkelstein, A. (2012) “The Oregon Health Study Group The Oregon Health Insurance Experiment: Evidence from the First Year”, *Quarterly Journal of Economics* 127 (3): 1057- 1106.

Baicker, Katherine, Sarah L. Taubman, Heidi L. Allen, Mira Bernstein, Jonathan H. Gruber, Joseph P. Newhouse, Eric C. Schneider, Bill J. Wright, Alan M. Zaslavsky, and Amy N. Finkelstein. 2013. “The Oregon Experiment – Effects of Medicaid on Clinical Outcomes.” *New England Journal of Medicine* 368: 1713–22.

Finkelstein, A., Hendren, N. and Luttmer, E. F.P. (2019)“The Value of Medicaid: Interpreting Results from the Oregon Health Insurance Experiment” Journal of Political Economy Vol. 127 No. 6

Einav, L. and Finkelstein, A.(2018)“Moral Hazard in Health Insurance: What We Know and How We Know It” Journal of the European Economic Association, 2018 vol 16(4), pages 957-982. (with Liran Einav)

Finkelstein, Amy, Nathaniel Hendren, and Mark Shepard. 2019. “Sub- sidizing Health Insurance for Low-Income Adults: Evidence from Massachusetts,” American Economic Review 109(4): 1530-1567.

5. Drugs. Pricing of new drugs [S8].

Kyle, M. (2019). “The Single Market in Pharmaceuticals”, Review of Industrial Organization, 55(1):111–135.

Dubois, P. and Saethre, M. (2020) “On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector”, Econometrica, vol. 88, n. 6, November 2020, pp. 2503–2545.

Thomas, Lacy Glenn, “Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals,” Industrial and Corporate Change, 1994, 3 (2), 451–489.

Danzon, P.M. (2019) “Drug Pricing and Value in Oncology”. In Regu- latory and Economic Aspects in Oncology, Recent Results in Cancer Research, edited by Evelyn Walter, (2019), pp. 153-167

Danzon, P.M. (2018) “Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues”, PharmacoEconomics, 36 (12), pp. 1395-1405. 10.1007/s40273-018-0696-4

Danzon, P.M. (2018), “Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases,and Cures”, Value in Health, 21, pp. 252-257.

DiMasi, J.A., Grabowski, H. G., Hansen, R. W. (2016) “Innovation in the pharmaceutical industry: New estimates of R&D costs”, Journal of Health Economics, Volume 47, 2016, Pages 20–33,

6. Different health market structures [S9].

Distance learning – Enseignement à distance :

Distance learning can be provided when necessary by implementing:

- *Interactive virtual classrooms*
- *Recorded lectures (videos)*
- *MCQ tests and other online exercises / assignments*

- *Remote (online) tutorials (classes)*
- *Chatrooms*

En cas de nécessité, un enseignement à distance sera assuré en mobilisant:

- *Classe en ligne interactive*
- *Vidéo enregistrée de la présentation du matériel pédagogique*
- *QCM et exercices en ligne*
- *TP/TD à distance*
- *Forum...*